Indel Therapeutics is a Vancouver, Canada–based biopharmaceutical company focused on discovering novel antibiotic drugs to address antibiotic resistance. Its pipeline targets difficult-to-treat and hospital-acquired infections. The company closed a $1.4m second round of financing to fund its programs. Indel intends to use the proceeds to advance several antibiotic programs through animal proof-of-concept studies. In connection with the financing, Allan Collings, a co-founder and principal of ACM Advisors Ltd., joined the company’s board of directors. No revenue or user metrics are reported in the article.

Total raised

$1M

Funding rounds

1

Latest round

Equity

Latest activity

Apr 2011